scholarly journals Iatrogenic Pulmonary Nodule in a Heart Transplant Recipient

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Atul C. Mehta ◽  
Juan Wang ◽  
Jarmanjeet Singh ◽  
Joseph Cicenia
Keyword(s):  
Transplant Recipient ◽  
Heart Transplantation ◽  
Heart Transplant ◽  
Pulmonary Nodule ◽  
Lung Nodule ◽  
Invasive Pulmonary Aspergillosis ◽  
Heart Transplant Recipient ◽  
Non Hodgkin Lymphoma ◽  
First Case ◽  
End Stage

A 58-year-old female with a history of non-Hodgkin lymphoma and end-stage nonischemic cardiomyopathy from Adriamycin toxicity underwent orthotic heart transplantation during June 2013. She developed shortness of breath in September 2013 and was suspected to have invasive pulmonary aspergillosis. A flexible bronchoscopy (FB) with a transbronchial biopsy (TBBx) was performed. She was found to have a focal lung nodule in the same location at the site of the TBBx on day 13 after the FB. Spontaneous resolution of the nodule was confirmed on the computed tomography (CT) scan of chest performed at 3 months. We believe that this nodule was as a consequence of the TBBx. Formation of a peripheral pulmonary nodule (PPN) following a TBBx is occasionally encountered among the recipients of the lung transplantation. To our knowledge, this is the first case of TBBx producing a pulmonary nodule in a heart transplant recipient. Physicians caring for the patients with heart transplantation should be cognizant of the iatrogenic nature of such nodule to avoid unnecessary diagnostic work-up.

scholarly journals The use of eculizumab as a bridge to retransplantation for chronic antibody-mediated rejection in a heart transplant recipient: a case report

2021 ◽  
Vol 5 (5) ◽  
Author(s):  
Katherine Kearney ◽  
Peter Macdonald ◽  
Christopher Hayward ◽  
Kavitha Muthiah
Keyword(s):  
New York ◽  
Heart Transplantation ◽  
Heart Transplant ◽  
Graft Function ◽  
Heart Association ◽  
Heart Transplant Recipient ◽  
Functional Class ◽  
Renal Transplant Recipients ◽  
Antibody Mediated Rejection ◽  
First Case

Abstract Background Antibody-mediated rejection (AMR) remains a major management challenge in heart transplantation given the complexity of pathological diagnosis and dearth of evidence for effective management. Eculizumab, an anti-C5 monoclonal antibody which inhibits terminal complement activation, has been reported to decrease early AMR in sensitized renal transplant recipients. Case summary We report a case of a 29-year-old gentleman with chronic AMR 8 years after heart transplantation, manifesting as significant graft dysfunction. Donor-specific antibodies to DQ7 were found to be causative. Antibody-mediated rejection was managed with quadruple oral immunosuppressive therapy (mycophenolate, prednisolone, everolimus, and tacrolimus) as well as a sequence of broad-spectrum immunological therapies; intravenous (IV) methylprednisolone, plasmapheresis, IV immunoglobulin, rituximab, bortezomib, tocilizumab, and splenic irradiation. No treatment had a sustained impact on donor-specific anti-HLA antibodies (DSAs) or graft function. After testing showed the DQ7 antibodies were complement-binding, a trial of eculizumab was started. This improved DSAs somewhat, and improved graft function and New York Heart Association functional class substantially. The patient was relisted for heart transplantation and successfully retransplanted in March 2018. Specifically, the new organ and recipient were matched at DQ7. After discontinuation of eculizumab, the patient has remained healthy and well, with normal graft function 28 months after retransplantation. Discussion To the best of our knowledge, this is the first case of chronic AMR in a heart transplant patient, successfully stabilized with eculizumab and bridged to retransplantation.

scholarly journals Hypertrophic obstructive cardiomyopathy in a heart transplant recipient: a case report

2021 ◽  
Vol 26 (3S) ◽  
pp. 4625
Author(s):  
G. A. Golovina ◽  
T. V. Stavenchuk ◽  
N. V. Kizhvatova ◽  
E. D. Kosmacheva
Keyword(s):  
Case Report ◽  
Transplant Recipient ◽  
Heart Transplantation ◽  
Heart Transplant ◽  
Heart Transplant Recipient ◽  
Hypertrophic Obstructive Cardiomyopathy ◽  
Orthotopic Heart Transplantation

The article presents a case report of developing the classic hypertrophic obstructive cardiomyopathy in a 66-year-old male heart transplant recipient within 5 years after orthotopic heart transplantation. The characteristics of this pathology are discussed.

scholarly journals Fatal West Nile Virus Encephalitis in a Heart Transplant Recipient

2015 ◽  
Vol 53 (8) ◽  
pp. 2749-2752 ◽  
Author(s):  
Adam J. Gomez ◽  
Jesse J. Waggoner ◽  
Megumi Itoh ◽  
Seth A. Hollander ◽  
Kathleen M. Gutierrez ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
West Nile Virus ◽  
Transplant Recipient ◽  
Heart Transplantation ◽  
Heart Transplant ◽  
Heart Transplant Recipient ◽  
Immunocompromised Patients ◽  
West Nile ◽  
Virus Encephalitis ◽  
West Nile Virus Encephalitis

The diagnosis of encephalitis is particularly challenging in immunocompromised patients. We report here a case of fatal West Nile virus encephalitis confounded by the presence of budding yeast in the cerebrospinal fluid (CSF) from a patient who had undergone heart transplantation for dilated cardiomyopathy 11 months prior to presentation of neurologic symptoms.

scholarly journals Kidney injury and renal replacement therapy in heart transplant recipient

2017 ◽  
Vol 19 (1) ◽  
pp. 52-56
Author(s):  
Ya. L. Poz ◽  
A. G. Strokov ◽  
V. N. Poptsov ◽  
Yu. V. Kopylova ◽  
K. N. Kryshin
Keyword(s):  
Renal Replacement Therapy ◽  
Transplant Recipient ◽  
Heart Transplantation ◽  
Replacement Therapy ◽  
Heart Transplant ◽  
Kidney Injury ◽  
Heart Transplant Recipient ◽  
Specific Patient ◽  
Heart Transplantations ◽  
Kidney Transplantations

The development of kidney injury and the characteristics of renal replacement therapy were considered in patient with dilated cardiomyopathy, who consequently underwent two heart transplantations and two kidney transplantations. Since the number of the patients needed both kidney and heart transplantation increases constantly, the multifaceted thorough research in this specific patient population is extremely important.

scholarly journals FatalToxoplasma gondiiDissemination in a Heart Transplant Recipient: Description of a Case

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
S. Mastrobuoni ◽  
A. M. Dell'Aquila ◽  
J. Herreros
Keyword(s):  
Toxoplasma Gondii ◽  
Transplant Recipient ◽  
Heart Transplantation ◽  
Heart Transplant ◽  
Respiratory Symptoms ◽  
Cardiac Involvement ◽  
Heart Transplant Recipient ◽  
Postmortem Examination ◽  
Blood Cultures ◽  
Atypical Pneumonia

A 45-year-old heart transplant recipient presented with fever, anorexia, asthenia, and lethargy. She had received heart transplantation only 5 weeks earlier for primary systemic amyloidosis with severe cardiac involvement. Serum sodium was low, and tacrolimus through level was high. Blood cultures and serology tests for infection were negative, and atypical pneumonia was suspected. Despite broad antibiotic, antiviral, and antifungal treatment, the patient clinical condition rapidly deteriorated and she died within three days of admission. Postmortem examination revealed a disseminatedToxoplasma gondiiinfection as a result of donor (+)/recipient(−) mismatch forToxoplasmaserology. Although very rare, toxoplasmosis in heart transplant recipient should be suspect in case of neurological deficit and respiratory symptoms. Prophylaxis treatment is recommended in case of mismatch.

Recurrent Asystole After Neostigmine in a Heart Transplant Recipient With End-Stage Renal Disease

2017 ◽  
Vol 31 (2) ◽  
pp. 653-656 ◽  
Author(s):  
Matthieu Cachemaille ◽  
Magnus Olofsson ◽  
Françoise Livio ◽  
Patrizio Pascale ◽  
Tobias Zingg ◽  
...  
Keyword(s):  
Transplant Recipient ◽  
Renal Disease ◽  
Heart Transplant ◽  
End Stage Renal Disease ◽  
Heart Transplant Recipient ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document